In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m 2 /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m 2 ; cycles 4-8, 500 mg/ m 2 ). Responders were randomized to 12 8-week doses of R (375 mg/m 2 ) or observation. As per intention-totreat analysis, 82.4% (95% CI, 74.25-90.46%) of 85 patients achieved an overall response (OR), 16.5% a complete response (CR), 2.4% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4%, B 81.6%, and C 78.6%) and age categories (60-64 years, 92.3%; 65-69, 85.2%; 70-74, 75.0%; 75, 81.0%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients.
Chlorambucil (CLB) remains therefore a widely used first-line treatment for such patients [3] , but has limited effectiveness as monotherapy, with overall response (OR) rates up to 75%, but uncommon complete responses (CRs) and short PFS [6] [7] [8] [9] . Management of elderly patients has remained a primary unmet need until recently, when evidence-based therapeutic strategies exploring the association between CLB and anti-CD20 monoclonal antibodies are being reported [10] [11] [12] .
Several biologic properties of CLL cells allow patient stratification into risk categories that predict PFS and OS [4, 13] . The impact of novel gene mutations (NOTCH1, SF3B1, and BIRC3) on CLL treatment outcome is currently under investigation.
We conducted a single-arm, phase II, open-label, multicenter study of CLB plus R (CLB-R) as induction, followed by a randomized maintenance with R or observation (protocol ML21445), to determine if CLB-R is feasible and beneficial as first-line treatment for elderly CLL patients. Treatment outcome has been correlated with biologic parameters, including gene expression profiling (GEP) and novel mutations. Furthermore, we explored the impact of R as maintenance treatment.
Methods
Patients. The study included patients aged >65 years (or 60-65 years not eligible for fludarabine-based regimens) with previously untreated CLL (Binet stage A or B with active disease or stage C), diagnosed according to the International Workshop on CLL (iwCLL) update of the National Cancer Institute (NCI) 1996 guidelines [14] . Exclusion criteria included: history of other malignancies within 2 years prior to study entry or severe cardiac disease, comorbidities requiring >1 month use of systemic corticosteroids, creatinine clearance <50 mL/min, or transformation to aggressive B-cell malignancy.
Study design and treatment. This study was designed to assess the efficacy and safety of CLB-R as induction therapy and explore the role of a maintenance phase with R or observation in responders. The primary endpoint was OR at the end of induction. Secondary endpoints included CR, CR with incomplete bone marrow recovery (CRi), and partial response (PR) at the end of the induction and OR, CR, and PR at the end of the maintenance phase, immunophenotypic CR, molecular CR, event-free survival (EFS), PFS, time to new CLL treatment (TTNT) or death, and OS, safety of the induction phase and the R maintenance arm, response and survival endpoints in biologically defined subgroups.
Response assessment was performed 2 months after induction completion. Definition of response was based on iwCLL criteria updating the NCI 1996 guidelines [14] . The first dose of R maintenance was scheduled 3 months after the last induction cycle in randomized patients.
The study was approved by the Institutional Review Board of the coordinating center and by the ethics committees of the 19 participating centers. All patients provided written informed consent. The trial was conducted in respect of the Helsinki Declaration, of Good Clinical Practice, and of applicable national regulations. The study period was from October 2008 to January 2013.
Treatment is detailed in Fig. 1a . Treatment modifications in case of cytopenia or adverse event (AE) are specified in Supporting Information.
Biologic work-up, including minimal residual disease (MRD) in CR patients, is detailed in the Supporting Information [15] [16] [17] [18] [19] [20] [21] [22] .
Statistical analysis. Based on an a-level of 0.05 to show a significant difference with respect to the primary endpoint of OR rate after the induction phase, the planned sample size has estimated from 72 to 94 subjects to obtain a power at least of 80% and a maximum of 90%.
The calculation of the sample size was based on the following assumptions:
-0.65 OR proportion in null hypothesis.
-0.80 OR proportion expected under alternative hypothesis.
Considering a 20% of non-evaluable subjects, from 90 to 118 subjects should have been included in the study.
Statistical testing was conducted at the two-sided a 5 0.05 level and two-sided 95% confidence intervals (CI) were used. To test the null hypothesis that the responders proportion was equal to 0.65 (H0: p t 5 0.65), the binomial distribution with the normal approximation was used (two-sided; a 5 0.05). A two-sided v 2 test and two-sided 95% confidence limits for response were used. Multivariate logistic regression and univariate analyses assessed the impact of biologic parameters on response rates. The Kaplan-Meier approach was used for time-related variables estimates. Estimates for the median time-to-event and the corresponding two-sided 95% CI were made together with the estimates for the other quartiles and the range. Multivariate Cox regression analysis assessed the impact of prognostic factors on survival endpoints and the impact of treatment group and prognostic factors on survival endpoints on the randomized population (see Supporting Information).
Results

Patients' characteristics
Ninety-seven patients entered the induction phase (safety population) and 85 received 1 dose of R (intention-to-treat, ITT population). Upon induction completion, 34 patients were randomized to R maintenance and 32 to observation (Fig. 1b) . Table I summarizes the characteristics of the ITT and the maintenance randomized population.
In the ITT population, the median age was 70 years (range: 61-84). Forty-four patients (51.8%) had 1 documented comorbidity at baseline: 6/13 patients aged 60-64 years (46.1%), 12/27 aged 65-69 (44.4%), 11/24 aged 70-74 (45.8%), 12/17 aged 75-79 (70.5%) and 3/ 4 aged 80 (75%).
Cytogenetic analysis using immunostimulatory CpG-oligonucleotide DSP30 plus interleukin-2 [16] identified 12 cases with complex karyotypes-that is, the presence of three or more cytogenetic aberrations in the same clone-5 of which devoid of 17p2/11q2.
Induction efficacy
The OR rate in the ITT population (N 5 85) was 82.4% (95% CI, 74.25-90.46%, n 5 70), with 16.5% (n 5 14) CR, 2.4% (n 5 2) CRi, 60.0% (n 5 51) PR, and 3.5% (n 5 3) nodular PR. 
Survival endpoints
The median follow-up of the ITT population was 34.2 months (range 3.0-43.5). The over 3-year PFS and EFS rates were 42.7% (95% CI, 27.3-57.4%) and 38.2% (95% CI, 24.4-51.9%), respectively ( Fig. 2a,b) . The median PFS and EFS were 34.7 (95% CI, 33.1-39.5) and 34.5 months (95% CI, 25.2-38.2), respectively. The median OS was not reached.
Induction safety
CLB was used at 56 mg/m 2 for 8 cycles (total dose: 448 mg/m 2 ). CLB dose reduction occurred in 51/657 cycles (7.8%), mostly for toxicity (40 cycles, 6.1%) and in 7/103 (6.7%), 18/210 (8.5%), 10/168 (5.9%), 14/136 (10.2%), and 2/40 cycles (5.0%) for patients aged 60-64, 65-69, 70-74, 75-79, and 80 years, respectively.
In the safety population (N 5 97), 76 patients (78.4%) had at least one AE during induction: 84.6% in patients aged 60-64 years, 75% aged 65-69, 80.7% aged 70-74, 70.0% aged 75-79, and 90.0% aged 80. Thirty-three of ninety-seven patients (34%) experienced general disorders, the most frequent being pyrexia (12.4%), infusion-related reaction (6.2%), fatigue (5.2%), asthenia (4.1%), and chest pain and influenza-like symptoms (3.1%). Nineteen serious AEs (SAE) occurred in seventeen patients (17.5%) during induction: 30.7% aged 60-64 years, 14.2% aged 65-69, 15.3% aged 70-74, 5% aged 75-79, and 40% aged 80. The most common was anemia. Of them, five were CLB-related (herpes zoster infection, erythematous rash, lumbar pain, anemia, and fever of unknown origin) and three CLB-R-related (pleural effusion, anemia, and neutropenia). One fatal SAE during induction (renal failure and paralytic ileus) was not considered treatment related. Eight other deaths occurred after induction interruption: three from disease progression/relapse, one each from pulmonary infection, spinocellular carcinoma, anaplastic oligoastrocytoma, respectively, and two from unknown causes.
Maintenance
Among the 66 randomized patients (4 CR/CRi and 30 PR/nPR in the R arm, 12 CR/CRi and 20 PR in the observation arm), the OR rate after maintenance was 55.9% (95% CI, 39.19-72.57%) in the R arm and 34.4% (95% CI, 17.92-50.83%) in the observation arm, respectively (P 5 0.079); the CR and PR rate were 29.4% and 26.4% in the R arm, and 18.7% and 12.5% in the observation arm, respectively. Notably, among the 50 PR/nPR patients randomized after induction, the proportion of responders to the R arm (17/30, 56.7%; 9 CR, 30%, 8 PR, 26.7%) was significantly higher than in the observation arm (5/20, 25%; 1 CR, 5%, 4 PR, 20%) (P 5 0.027).
At R maintenance completion, 5/10 CR were evaluated for MRD: one proved MRD2 in the PB and BM both immunophenotypically and molecularly, two were MRD2 by flow in the PB and MRD1 in the BM; two were MRD1 in both compartments. All of them were in PR after induction (four PR, one nPR). At completion of the observation arm, none of the six CR patients was MRD2: four CR with MRD1 after induction experienced a MRD level increase, one MRD2 CR after induction became MRD1, one PR after induction achieved a MRD1 CR.
In the randomized population, the median follow-up was 34.9 months (34.4 and 35.2 months for R and observation arm, respectively). The over 3-year PFS and median PFS rates were 48.6% and 38.2 months for R arm and 31.8% and 34.7 months for observation arm, respectively. There was a trend towards a longer PFS for patients receiving R maintenance (P 5 0.07) (Fig. 2c) .
In the R maintenance arm, 73.5% patients had at least one AE compared to 56.3% in the observation arm, with no significant difference (P 5 0.141); no differential distribution of AE was recorded according to age. No difference in neutropenia (P 5 0.101) or infections was recorded between the two arms (Table II) . Ten SAE occurred in eight patients (12.1%) during maintenance, with an equal distribution according to arm and only one was R treatment-related (neutropenia). No fatal SAE occurred during maintenance; three patients (one in the R arm for lymphoma, two in the observation arm for disease progression/relapse and second tumor, respectively) died after maintenance interruption.
Biologic characteristics and patients' outcome
Univariate analysis in the population with response assessment (N 5 77) evaluated the impact of prognostic factors on OR (Supporting Information Table SI) and CR (Supporting Information Table SII) achievement after induction and on PFS.
Only TP53 disruption and a new model including complex karyotype within the high-risk FISH category (17p2 and 11q2) were significantly associated to a poor response (each P 5 0.022). The latter also predicted CR achievement (P 5 0.0225). Contrariwise, 11q2 was not associated to a poor response (P 5 0.403): 13/15 patients (86.7%) achieved a response, including 3 CR and 10 PR.
Immunoglobulin heavy chain variable region gene (IGHV) mutations were the only significant predictor of PFS (P 5 0.0011), with unmutated CLL having a 6.12 (2.070-18.077) higher risk of progression than mutated CLL.
Univariate analysis on the randomized population (N 5 66) showed a significant difference in OR according to the IGHV mutation status in the observation arm (OR, 60% for mutated IGHV CLL vs. 12.5% for IGHV unmutated cases, P 5 0.009) but not in the R arm (OR, 69.2% for mutated IGHV CLL vs. 45.0% for unmutated IGHV cases, P 5 0.284), and according to the maintenance arm among unmutated IGHV patients (P 5 0.067) but not among mutated IGHV CLL (P 5 0.705). Consistently, a significantly different PFS within unmutated IGHV patients according to the maintenance arm was found (P 5 0.012): the median PFS was 38.2 months (95% CI, 30.4-39.5) and 22.8 (95% CI, 20.1-33.1), respectively, for R and the observation arm.
A similar trend was observed for 112 CLL (OR, 66.67% in the R arm vs. 14.3% in the observation arm, P 5 0.06). On multivariate analysis on the randomized population, unmutated IGHV independently predicted a significantly shorter PFS (P 5 0.0048) and TTNT (P 5 0.0189). Maintenance arm and 13q2 showed a trend towards significance for PFS (P 5 0.0747 and P 5 0.0512, respectively).
Novel gene mutations and patients' outcome
Novel gene mutations were evaluable in 74 cases with response assessment. Nine patients were NOTCH1 mutated: all responded to induction and 44% achieved a CR, with no significant difference with wild-type cases. Nine showed SF3B1 mutations: 8/9 responded, not differently from wild-type cases; however, only 1/9 (11%) SF3B1 mutated cases obtained a CR, as opposed to 14/65 (21.5%) wild-type cases. Similarly, 7/8 BIRC3 mutated/deleted patients had an OR, with only 1 CR. For each mutation, PFS was assessed stratifying patients according to the presence of: (1) one of the novel mutations; (2) TP53 disruption; (3) no mutations/disruptions. Only SF3B1 mutations showed a trend towards a shorter PFS (P 5 0.0761).
Neither in the R or observation arm, a significant impact on response was recorded according to the presence of mutations in 65 evaluable cases. not cluster according to their clinical responses either by unsupervised analysis or when comparing the three groups by ANOVA (not shown).
GEP and response to therapy
Contrariwise, the ANOVA analysis of CR versus NR patients (Supporting Information Fig. S1A ) highlighted a homogeneous signature in the NR group, where two patients with concomitant 17p2 and TP53 mutation displayed the strongest signature. DAVID functional analysis revealed an overrepresentation of apoptotic (P < 0.0001) and antiapoptotic pathways (P < 0.0001) (Supporting Information Fig. S1B ).
Anti-apoptotic and pro-proliferative genes were more represented in the NR group, with the upmodulation of the Ras and Rho pathways; indeed, the upregulation of KRAS, EP300, and NRAS (Supporting Information Table SIII ) was confirmed by quantitative PCR, particularly in the PD patients (not shown). NR patients also showed a significant downmodulation of the CD20 transcript, that correlated with CD20 mean fluorescence intensity (Pearson correlation coefficient 5 0.57). However, the correlation of the latter with response did not reach statistical significance (Supporting Information Fig. S2) .
Among PR patients after induction who received R maintenance (n 5 21), GEP analysis showed a clusterization according to their clinical response after maintenance, with a distinctive signature for the NR patients, again including the upmodulation of anti-apoptotic genes (Supporting Information Fig. S1C ).
Discussion
The primary objective of this study was to evaluate the efficacy of CLB-R induction on OR achievement in elderly CLL patients. The trial provided very satisfactory results: the response rate-82.4% OR, including 16.5% CR and 2.4% CRi, with cytometric MRD2 in 14% of CR cases-compares favorably with the 31-55% OR rates of trials using single-agent CLB at comparable doses [7, 8, 23] , the 72% OR of the LRF CLL4 trial, using higher doses of single-agent CLB [6] and is supported by a similar British trial using CLB-R (OR 82%) [11] . Furthermore, in our study, PFS (34.7 months) is higher than that reported in trials using single-agent CLB (8.3-18 months) [6] [7] [8] 12, 23] . A preliminary analysis of the German CLL11 trial, comparing CLB alone, obinutuzumab 1 CLB, and CLB-R in untreated CLL patients with comorbidities, has been released [12] . The CLB-R arm provides inferior results (OR 65%, CR 7%, PFS 15.2 months) compared to ours, probably due to the lower CLB dosage/cycle and number of cycles. Interestingly, our OR and EFS results are also not inferior to those achieved by bendamustine plus R, although with less CR, and with a remarkably lower grade 3-4 hematologic toxicity [24] . Even though these comparisons have strong limitations due to different age inclusion criteria, CLB dosage, and treatment duration [9] , it is worth noting that our study included patients with a median age of 70 years and is the only one including the maintenance with R [25] [26] [27] .
At variance from fludarabine-based regimens, CLB-R was well tolerated: over three-quarter of patients completed all 8 induction cycles, regardless of age. CLB dose reduction was needed in 7.8% of cycles, due to toxicity in 6.1%.
In our study, AEs were generally hematologic, with neutropenia being the most common and affecting approximately one-third of patients in induction. Infections occurred in 15.5% of patients, although rarely of grade 3-4 (1%). Thus, CLB-R toxicity compares favorably with other trials using CLB alone or with R [6] [7] [8] 11, 23] . Infusion-related side effects were limited.
The role of maintenance in CLL is still an open issue, so far investigated by the use of monoclonal antibodies or lenalidomide. As in other chronic B-cell malignancies, the use of R after induction chemotherapy suggests a benefit in sustaining the response duration in CLL patients [28] [29] [30] [31] . Most of the published studies used R after fludarabine-based regimens; the most recent one after FCR plus mitoxantrone, with a remarkable efficacy but a relevant hematologic Only AE judged clinically relevant and/or more frequent within safety population were selected.
and infectious toxicity [31] . Our study is the first to explore R maintenance after CLB-R induction. Although we could not formally demonstrate a clear advantage of R maintenance in responders after CLB-R induction, as maintenance was not the primary objective of the study, a better PFS was recorded compared to the control arm. In particular, PR/nPR patients after induction completion benefitted the most from R maintenance in terms of response improvement. Moreover, R maintenance determined a MRD clearing in induction responders in contrast to the observation arm, where MRD levels increased in all patients. Remarkably, under R maintenance AE, SAE, neutropenia, or infections were as frequent as in the observation arm. Infections were the most common AE during maintenance, affecting one-fourth of patients, although never of grade 3-4. This supports the feasibility of maintenance strategies in elderly and/or unfit patients provided that the induction is not intensive and/or immunosuppressive [31] .
Among several biologic markers, most had a limited value in predicting response to CLB-R, with the exception of genetic abnormalities. 17p2/TP53 mutations and complex karyotype were significantly associated to a poor response and CR rate. Contrariwise, our data suggest that an induction therapy combining R and an alkylating agent may be beneficial for 11q2 patients who are elderly and/or unfit for FCR [32] .
Neither NOTCH1, SF3B1, or BIRC3 mutations impacted on OR after induction, in line with other reports [33, 34] ; however, SF3B1 mutations and BIRC3 disruption were rarely detected in CR patients.
The only biologic marker significantly associated to a worse PFS was an unmutated IGHV status, although this did not impact on response to induction. Unmutated IGHV independently predicted a shorter PFS and TTNT also among randomized patients. However, the significant difference in response and PFS according to the IGHV mutational status found in the observation arm but not in the R arm suggests a benefit for unmutated IGHV in receiving R maintenance.
GEP may be useful in predicting response to induction and to R maintenance. NR patients in induction displayed a distinct signature from that of CR patients, with the concomitant downmodulation of pro-apoptotic and upmodulation of anti-apoptotic and proproliferative genes. Of interest is the overexpression of KRAS and NRAS [35] , and the downmodulation of the CD20 gene in NR patients. The latter observation, in line with in vitro [36] and in vivo data [31] , suggests that higher doses or new anti-CD20 antibodies may be beneficial in biologically identified subsets of patients.
In conclusion, this study shows that: (i) CLB-R induction is an active first-line treatment for elderly CLL patients, regardless of age and disease stage; (ii) the toxicity is limited and manageable, regardless of age; (iii) PFS is promising and higher than that reported with CLB alone; (iv) CLB-R seems active also among 11q2 patients; (v) NR patients may be identified by TP53 abnormalities/complex karyotype, a distinctive GEP, and low CD20 gene expression; (vi) IGHV mutations strongly influence PFS; (vii) low CR rates are recorded among SF3B1 mutated and BIRC3 disrupted cases. Moreover, we suggest that R maintenance is doable in elderly CLL patients and tends to improve PFS in patients responders to a CLB-R induction, not increasing toxicity compared to observation in terms of AE, SAE, neutropenia, or infections. It seems beneficial mostly in PR/nPR patients after induction in terms of response improvement and in unmutated IGHV patients. Therefore, we support the need of prospective phase III clinical trials to conclusively define the role of maintenance in maintaining response and prolonging survival also in elderly CLL patients. Rituximab, ofatumumab, and obinutuzumab are the candidates that deserve a comparison in this context.
